Alder BioPharmaceuticals® to Present at the Morgan Stanley 15th Annual Global Healthcare Conference

BOTHELL, Wash., Sept. 05, 2017 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. ALDR, a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics today announced that it will webcast its presentation at the upcoming Morgan Stanley 15^th Annual Global Healthcare Conference at 8:35 a.m. ET on Tuesday, September 12, 2017 in New York, NY. The presentation will feature a business overview and update by Randall C. Schatzman, Ph.D., president and chief executive officer.

A live audio webcast can be accessed on the Events & Presentations page of the Investors section of Alder's website at http://www.alderbio.com, or by following the link below in your web browser. An archived replay of the webcast will be available on Alder's website for 30 days after the live event concludes.

Link: https://cc.talkpoint.com/morg007/091117a_as/?entity=77_PRHVMBI

About Alder BioPharmaceuticals, Inc.

Alder BioPharmaceuticals, Inc. is a clinical-stage biopharmaceutical company committed to transforming the treatment paradigm for patients with migraine and other serious neurological or inflammatory conditions. Leveraging its pioneering monoclonal antibody technologies, Alder discovers and develops novel therapeutic antibodies designed to deliver highly differentiated, best-in-class clinical profiles. Alder's lead pivotal-stage product candidate, eptinezumab, is being evaluated for migraine prevention. Eptinezumab is a monoclonal antibody administered quarterly via infusion that allows for 100% of the dose available to selectively and potently inhibit the calcitonin gene-related peptide (CGRP), a protein that is active in mediating the initiation of migraine. Alder is additionally evaluating ALD1910, a preclinical product candidate also in development as a migraine prevention therapy. ALD1910 is a monoclonal antibody that inhibits pituitary adenylate cyclase-activating polypeptide-38 (PACAP-38), another protein that is active in mediating the initiation of migraine. Clazakizumab, Alder's third program, is a monoclonal antibody candidate that inhibits interleukin-6 and is licensed to Vitaeris, Inc. For more information, please visit http://www.alderbio.com.  

Media Contact:				
David Schull				
Russo Partners, LLC			
(212) 845-4271				
david.schull@russopartnersllc.com

Investor Relations Contact:
David Walsey
Alder Biopharmaceuticals
(425) 408-8032
ir@alderbio.com